Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06269380
Other study ID # 30.01.2024-4274
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 13, 2024
Est. completion date February 21, 2024

Study information

Verified date February 2024
Source Sisli Hamidiye Etfal Training and Research Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Esophagogastroduodenoscopy (EGD) is commonly performed in patients presenting with abdominal pain and dyspeptic symptoms, serving as a valuable diagnostic and therapeutic tool. While various methods are available for biopsy sampling when mucosal pathology is observed during EGD, the practice of obtaining biopsies from endoscopically normal mucosa remains controversial. Although there is literature suggesting that routine biopsies from the antrum and duodenum for surveillance purposes increase costs, pathological findings can sometimes be detected in areas that appear normal on mucosal examination, leading to potential changes in treatment approach if biopsies are obtained. In this study, a retrospective evaluation of the prevalence of various pathologies detected in biopsies obtained from endoscopically normal mucosa in patients who underwent EGD was reported as normal.


Description:

Esophagogastroduodenoscopy (EGD) is a commonly used diagnostic tool in upper gastrointestinal system diseases. Its widespread use is facilitated by its minimally invasive nature, the possibility of therapeutic procedures, low complication rates, and broad applicability. Although there are numerous guidelines regarding approaches to endoscopic pathologies and diseases detected during esophagogastroduodenoscopy, the necessity of biopsy sampling from mucosal areas that are endoscopically normal remains controversial. In this study, patients aged between 18 and 95 who underwent EGD at the Sisli Hamidiye Etfal Training and Research Hospital Surgical Endoscopy Unit between 2021 and 2023, with no pathology detected during the endoscopic examination and who underwent biopsy sampling, will be evaluated. History of upper gastrointestinal surgery, detection of the endoscopic pathology, and not having biopsy sampling will be considered as exclusion criteria. The rate of detection of histopathological findings in the obtained biopsies, severity and activity of gastritis, rate and density of Helicobacter pylori detection, and rate and extent of intestinal metaplasia will be evaluated.


Recruitment information / eligibility

Status Completed
Enrollment 671
Est. completion date February 21, 2024
Est. primary completion date February 20, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 95 Years
Eligibility Inclusion Criteria: - Patients aged between 18-95 - Endoscopically normal esophagogastroduodenoscopy - Sampling biopsies must be obtained Exclusion Criteria: - History of upper gastrointestinal surgery - Abnormal endoscopic findings such as gastritis, ulcer, hiatal hernia, pyloric deformity, alkaline reflux - Not having biopsy

Study Design


Intervention

Procedure:
Esophagogastroduodenoscopy
During the procedure, endoscopic examination of the upper gastrointestinal tract was made. Biopsy sampling can be made during procedure if endoscopist deemed necessary.
Endoscopic biopsy sampling
The obtaining of biopsy samples for control purposes despite the absence of endoscopic pathology during esophagogastroduodenoscopy.

Locations

Country Name City State
Turkey Sisli Hamidiye Etfal Research and Training Hospital Istanbul

Sponsors (1)

Lead Sponsor Collaborator
Sisli Hamidiye Etfal Training and Research Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of abnormal histopathologic findings Rate of abnormal histopathologic findings in patients with normal esophagogastroduodenoscopy and sampling biopsies obtained 2 week after esophagogastroduodenoscopy
Secondary Rate of intestinal metaplasia Rate of intestinal metaplasia in patients with normal esophagogastroduodenoscopy and sampling biopsies obtained 2 week after esophagogastroduodenoscopy
Secondary Rates of gastritis severity and activity Rate of gastritis severity and activity in patients with normal esophagogastroduodenoscopy and sampling biopsies obtained 2 week after esophagogastroduodenoscopy
Secondary Rate of Helicobacter Pylori positivity Rate of Helicobacter Pylori positivity in patients with normal esophagogastroduodenoscopy and sampling biopsies obtained 2 week after esophagogastroduodenoscopy
See also
  Status Clinical Trial Phase
Recruiting NCT03554356 - Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE) N/A
Recruiting NCT01398579 - Comparison Between Probe-based Confocal Laser Endomicroscopy, White-light Endoscopy and Virtual Chromoendoscopy Phase 1
Completed NCT01614418 - Radiofrequency Ablation for Gastric Metaplasia and Dysplasia Phase 1/Phase 2
Completed NCT06282484 - A Study on the Relationship Between Gastric Xanthoma and Gastric Cancer and Precancerous Lesions
Not yet recruiting NCT06085677 - The Gastric HormonE BioMarkers of Preneoplastic Lesions Study
Completed NCT01024621 - Confocal Laser Endomicroscopy for the Detection of Gastric Intestinal Metaplasia: a Randomized Controlled Trial N/A
Terminated NCT05579444 - Systems Biology of Gastrointestinal and Related Diseases
Recruiting NCT04331951 - Sensitivity of Targeted Biopsy Within Sydney Protocol for GIM N/A
Completed NCT03188406 - Gastric Cancer Precursor Lesions (GCPL) Study
Recruiting NCT05053945 - Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study
Completed NCT02075905 - Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management N/A
Completed NCT01374074 - Racial Disparity in Barrett's Esophagus N/A
Recruiting NCT02457624 - Gastric Cancer Screening Quality Improvement System Establishment N/A
Recruiting NCT05818072 - The Prevalence, Risk Factors and Optimal Biopsy Protocol of BE N/A
Completed NCT04296513 - Diagnosis of Gastritis, H. Pylori Infection and Atrophic Gastritis in Dyspeptic Patients
Completed NCT01896310 - New Classification of Stomach Using Probe-based Confocal Laser Endomicroscopy N/A
Completed NCT01373125 - Is the Neosquamous Epithelium "Normal" Following Endoscopic Ablation of Dysplastic Barrett's Esophagus? N/A
Completed NCT03976739 - Study on the Effect of Bile Reflux on Gastric Cancer and Its Precancerous Lesions: a Cross-sectional Study.
Recruiting NCT04054713 - Acetic Acid for the Detection of Esophageal Neoplasms N/A
Terminated NCT02788214 - Helicobacter Pylori Genome Project (HpGP)